Instem has published a short trading update for the year to December 2016. The outcome was in line with (and in some areas slightly ahead of) our expectations. The year was impacted by the slowdown in early phase Clinical, and a number of contracts being delayed into 2017, but strong performance in particular came from the SEND submit product range. We make no changes to our 2017 forecasts which should benefit both from the signing of the delayed contracts, and the ongoing (and growing) boost from adoption of the SEND standard.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
2016 outturn as expected; SEND on track
- Published:
16 Jan 2017 -
Author:
Gareth Evans -
Pages:
3
Instem has published a short trading update for the year to December 2016. The outcome was in line with (and in some areas slightly ahead of) our expectations. The year was impacted by the slowdown in early phase Clinical, and a number of contracts being delayed into 2017, but strong performance in particular came from the SEND submit product range. We make no changes to our 2017 forecasts which should benefit both from the signing of the delayed contracts, and the ongoing (and growing) boost from adoption of the SEND standard.